Clinical Report: Cellares and City of Hope to Automate CAR T Cell Therapy

Overview

Cellares and City of Hope are collaborating to automate the manufacturing of CAR T cell therapy targeting glioblastoma multiforme. This partnership aims to enhance the scalability and reproducibility of CAR T therapies, addressing the challenges of treating this aggressive brain cancer, with Cellares providing its automated manufacturing technology.

Background

Glioblastoma multiforme is a highly aggressive brain tumor with limited treatment options, including surgery, radiation, and chemotherapy, and a global incidence of approximately 300,000 new cases annually. The development of effective therapies, such as CAR T cell therapy, is crucial given the tumor's immunosuppressive environment and antigen heterogeneity. Automation in manufacturing processes is essential to meet the growing demand for these innovative treatments.

Data Highlights

Key Findings

• Cellares and City of Hope are collaborating to evaluate automated CAR T cell therapy manufacturing.
• City of Hope has expertise in CAR T therapies specifically targeting glioblastoma.
• The collaboration aims to establish scalable manufacturing processes to meet global patient demand.
• Automation is expected to enhance reproducibility and lower failure rates in CAR T cell production.
• Glioblastoma presents unique challenges due to its immunosuppressive microenvironment and antigen variability.

Clinical Implications

The collaboration between Cellares and City of Hope highlights the importance of automation in the development of CAR T therapies for solid tumors. Clinicians should be aware of the advancements in manufacturing processes that may enhance patient access to these innovative treatments in the future, potentially leading to improved outcomes.

Conclusion

The partnership between Cellares and City of Hope represents a significant step towards improving the manufacturing of CAR T cell therapies for glioblastoma. This initiative may pave the way for more effective treatment options for patients with this challenging disease, addressing the urgent need for scalable and reproducible therapies.

References

1. City of Hope, City of Hope Newsroom, 2023 -- Cellares and City of Hope to Automate Manufacturing of Solid Tumor CAR T Cell Therapy
2. the medicine maker, Sartorius Unveils Platform Aimed at Scaling Autologous Cell Therapy, 2026 -- Sartorius Unveils Platform Aimed at Scaling Autologous Cell Therapy
3. the medicine maker, Manufacturing Inside the Patient, 2026 -- Manufacturing Inside the Patient
4. The ASCO Post, New Data on ALK Inhibitors and CAR T-Cell Therapies, 2018 -- New Data on ALK Inhibitors and CAR T-Cell Therapies
5. the medicine maker — New Collaboration to Automate Cell Therapy Manufacturing with Robotics
6. Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
7. Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial - PMC
8. City of Hope and Cellares to Automate Manufacturing of Solid Tumor CAR